Targeted therapy revolutionized the treatment of EGFR mutant non–small cell lung cancer (NSCLC) with improved response rates over standard chemotherapy, and has become the standard first‐line treatment for patients harboring EGFR mutations.2 Here, EGFR is linked to non-small cell lung carcinoma.